跳转至内容
Merck
CN

286850

炔诺酮

98%

别名:

17α-乙炔基-19-去甲睾酮, 17-羟基-19-去甲-17α-孕甾-4-烯-20-炔基-3-酮, 17α-乙炔基-17β-羟基-19-去甲-4-雄甾烯-3-酮, 19-去甲-17α-乙炔基-4-雄甾烯-17β-醇-3-酮, 去甲基脱氢羟孕酮

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C20H26O2
化学文摘社编号:
分子量:
298.42
EC Number:
200-681-6
UNSPSC Code:
12352103
MDL number:
Beilstein/REAXYS Number:
1915671
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

assay

98%

optical activity

[α]20/D −24°, c = 1 in chloroform

mp

205-206 °C (lit.)

SMILES string

[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4(O)C#C

InChI

1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

InChI key

VIKNJXKGJWUCNN-XGXHKTLJSA-N

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

炔诺酮是用于抑制细胞溶质磺基转移酶类 (SULT) 的口服避孕药。

法规信息

新产品

此项目有


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Artem Cherkasov et al.
Journal of medicinal chemistry, 51(7), 2047-2056 (2008-03-12)
A benchmark data set of steroids with known affinity for sex hormone-binding globulin (SHBG) has been widely used to validate popular molecular field-based QSAR techniques. We have expanded the data set by adding a number of nonsteroidal SHBG ligands identified
Tiago L Moda et al.
Bioorganic & medicinal chemistry, 15(24), 7738-7745 (2007-09-18)
A drug intended for use in humans should have an ideal balance of pharmacokinetics and safety, as well as potency and selectivity. Unfavorable pharmacokinetics can negatively affect the clinical development of many otherwise promising drug candidates. A variety of in
Markus A Lill et al.
Journal of medicinal chemistry, 48(18), 5666-5674 (2005-09-02)
We investigated the influence of induced fit of the androgen receptor binding pocket on free energies of ligand binding. On the basis of a novel alignment procedure using flexible docking, molecular dynamics simulations, and linear-interaction energy analysis, we simulated the
Sean Ekins et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(12), 2302-2308 (2010-09-17)
Drug-induced liver injury (DILI) is one of the most important reasons for drug development failure at both preapproval and postapproval stages. There has been increased interest in developing predictive in vivo, in vitro, and in silico models to identify compounds
Nigel Greene et al.
Chemical research in toxicology, 23(7), 1215-1222 (2010-06-18)
Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持